From Compliance to Competitive Advantage: Unlocking the Business Value of Pharmacovigilance
Day 1 Global Pharma Outlook Stage
06/10/2026 15:45 - 16:10pm
Contributors
Lina Valero : PV Head LATAM - Opella Healthcare- Sanofi CHC
Pharmacovigilance (PV) is often perceived by small and emerging pharmaceutical companies as a regulatory obligation rather than a strategic investment. However, in an increasingly complex and transparent healthcare ecosystem, PV can serve as a powerful enabler of business growth, market access, and long-term sustainability.
This session will explore how pharma organisations can transform PV from a cost centre into a value-generating function. Through practical examples and industry-aligned frameworks, the session will address how effective drug safety systems contribute to risk mitigation, regulatory trust, faster approvals, enhanced corporate reputation and value creation.
The discussion will also highlight how early and proportionate investment in PV infrastructure can prevent costly remediation, support lifecycle management, and strengthen partnerships with regulators and stakeholders. Attendees will gain actionable insights into implementing scalable PV models tailored to their size, maturity, and portfolio complexity.